和黄医药：公司信息更新报告：呋喹替尼全球销售超4亿美元，公司实现盈利-20250321

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company achieved profitability in 2024 with total revenue of $630 million, driven by strong overseas sales of its core product, furmonertinib, which exceeded expectations [6] - The company expects combined revenue from its oncology/immunology business to be between$350 million and $450 million in 2025, with global sales of furmonertinib surpassing$400 million [7] - The company has adjusted its net profit forecasts for 2025-2027, projecting net profits of $2.383 billion,$797 million, and $961 million respectively [6] Financial Performance - In 2024, the company reported a net profit of$38 million, marking a return to profitability [6] - The revenue from oncology products reached $272 million in 2024, a year-on-year increase of 65$291 million in 2025, a year-on-year increase of 1825%, while domestic sales were $115 million, up 7$2.7, $0.9, and$1.1 respectively [6]